Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Molecular Cancer Therapeutics
|
March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M Briere, Shuai Li, Andrew Calinisan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Marcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Molecular Cancer Therapeutics
|
March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M Briere, Shuai Li, Andrew Calinisan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Marcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 1